Theramex and Asieris strike deal for drug-device combo Cevira
Theramex is paying $250 million for rights to Cevira, Asieris' drug-device treatment for cervical lesions.
London-based specialty pharmaceutical company focused solely on women's health, with products spanning contraception, fertility, menopause and osteoporosis and a presence in more than 80 countries.
Completion of Cevira rights acquisition from Asieris
Theramex is paying $250 million for rights to Cevira, Asieris' drug-device treatment for cervical lesions.
Chief Executive Officer